Samsung BiologicsLtd Full Year 2023 Earnings: EPS: ₩12,051 (vs ₩11,442 in FY 2022)

Samsung BiologicsLtd (KRX:207940) Full Year 2023 Results

Key Financial Results

• Revenue: ₩3.69t (up 23% from FY 2022).
• Net income: ₩857.7b (up 7.5% from FY 2022).
• Profit margin: 23% (down from 27% in FY 2022). The decrease in margin was driven by higher expenses.
• EPS: ₩12,051 (up from ₩11,442 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Samsung BiologicsLtd Earnings Insights

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in Asia.

Performance of the market in South Korea.

The company's shares are down 4.9% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Samsung BiologicsLtd's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.